IMNN - Imunon, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

IMNN

IMUNON, INC.

NASDAQ

$1.14

▲ UP 1.79% (0.02)

KEY STATISTICS

Market Cap$4.66 M

52w High$5.40

52w Low$1.10

Dividend Yield—

Frequency—

P/E-0.30

Volume106.14K

Shares Out.4.20M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Stacy R. Lindborg

COMPENSATION 2026

Salary$568,139

Stock Awards$0

Incentive Plan Pay$357,210

All Other Comp.$0

Total$1,029,349

ABOUT

SECTOR

Healthcare

WENT PUBLIC

March 1, 1999

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$10.00

Target Low$10.00

Target Median$10.00

Target Consensus$10.00

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.—

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2025-07-25	Reverse	1:15
2022-03-01	Reverse	1:15
2017-05-30	Reverse	1:14
2013-10-29	Reverse	111:500
2006-02-28	Reverse	1:15

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

VXF

0.00%

47.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED

11.83%

HOLDERS

TOP 8 OF 16 · RANKED BY POSITION SIZE

Armistice Capital, LLC

Riverview Capital Advisers, LLC

34.4K sh

$247.76K

Geode Capital Management, LLC

Wells Fargo & Company/Mn

PRICE

$1.14 ▲ UP 1.79% (+$0.02)

OVERLAYS

About Imunon, Inc.

https://www.imunon.com ↗

Imunon, Inc. is a biotech company developing DNA-based immunotherapies, vaccines, and chemotherapies, including GEN-1 for ovarian cancer and ThermoDox, with platform technologies for nucleic acid-based cancer treatments.

INDUSTRY

Biotechnology

A PRODUCT IMUNON, INC. IS KNOWN FOR

IMNN-001

IMNN-001, Imunon's lead DNA-based immunotherapy using TheraPlas® to deliver IL-12, is in Phase 3 trials for localized treatment of advanced ovarian cancer.

COMPETITORS

COMPETITOR

Imunon in 2025

SENTIMENT: + POSITIVE

INNOVATION · MAY 2025

Imunon Announces Positive Phase 2 Ovarian Cancer Treatment Results, Sparking 175% Stock Surge

Imunon, Inc. captured the spotlight in May 2025 with the announcement of positive results from its Phase 2 OVATION 2 study for its lead candidate, IMNN-001, in patients with advanced ovarian cancer. The data, which was later presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated a clinically meaningful 13-month extension in median overall survival. This announcement led to a dramatic 175% rally in the company's stock price, generating significant investor interest and media coverage.

PRODUCT LAUNCH · Q3 2025 · IN PROGRESS

Imunon Bets its Future on Ovarian Cancer Drug, Launching Pivotal Phase 3 Trial

In 2025, Imunon's most significant strategic shift was its full commitment to advancing its lead immunotherapy candidate, IMNN-001, into a pivotal Phase 3 trial (OVATION 3) for advanced ovarian cancer. This decision concentrates the company's resources on its most promising asset, effectively making the trial's outcome the primary determinant of Imunon's future success and potential commercialization. This was further emphasized by the strategic de-prioritization of its COVID-19 vaccine program, for which the company is now seeking partners to fund further development. [9, 20]